# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
0, Journal, 0, 13, "Diabetes Care", "", "<http://ctro/data#Publication_49816> <http://ctro/data#hasJournal> \"Diabetes Care\"."
1, PublicationYear, 16, 20, "2013", "", "<http://ctro/data#Publication_49816> <http://ctro/data#hasPublicationYear> \"2013\"."
14, Title, 102, 252, "Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes : a ≥ 52 - week randomized , double - blind study .", "", "<http://ctro/data#Publication_49816> <http://ctro/data#hasTitle> \"Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes : a ≥ 52 - week randomized , double - blind study .\"."
2, Linagliptin, 120, 131, "linagliptin", "", 
32, Insulin, 141, 148, "insulin", "", 
13, Precondition, 161, 200, "inadequately controlled type 2 diabetes", "", 
8, Type2Diabetes, 185, 200, "type 2 diabetes", "", "<http://ctro/data#ClinicalTrial_49823> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
10, Duration, 205, 216, "≥ 52 - week", "", "<http://ctro/data#ClinicalTrial_49823> <http://ctro/data#hasCTduration> \"≥ 52 - week\"."
11, Randomized, 217, 227, "randomized", "", "<http://ctro/data#ClinicalTrial_49823> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
12, DoubleBlind, 230, 244, "double - blind", "", "<http://ctro/data#ClinicalTrial_49823> <http://ctro/data#hasCTDesign> <http://ctro/data#DoubleBlind>."
15, Author, 253, 271, "Yki - J ä rvinen H", "", "<http://ctro/data#Publication_49816> <http://ctro/data#hasAuthor> \"Yki - J ä rvinen H\"."
16, Author, 280, 292, "Rosenstock J", "", "<http://ctro/data#Publication_49816> <http://ctro/data#hasAuthor> \"Rosenstock J\"."
17, Author, 295, 313, "Dur á n - Garcia S", "", "<http://ctro/data#Publication_49816> <http://ctro/data#hasAuthor> \"Dur á n - Garcia S\"."
18, Author, 316, 326, "Pinnetti S", "", "<http://ctro/data#Publication_49816> <http://ctro/data#hasAuthor> \"Pinnetti S\"."
19, Author, 329, 343, "Bhattacharya S", "", "<http://ctro/data#Publication_49816> <http://ctro/data#hasAuthor> \"Bhattacharya S\"."
20, Author, 346, 356, "Thiemann S", "", "<http://ctro/data#Publication_49816> <http://ctro/data#hasAuthor> \"Thiemann S\"."
21, Author, 359, 366, "Patel S", "", "<http://ctro/data#Publication_49816> <http://ctro/data#hasAuthor> \"Patel S\"."
22, Author, 369, 378, "Woerle HJ", "", "<http://ctro/data#Publication_49816> <http://ctro/data#hasAuthor> \"Woerle HJ\"."
23, Finland, 485, 487, "fi", "", 
28, ObjectiveDescription, 502, 678, "To evaluate the efficacy and long - term safety of linagliptin added to basal insulins in type 2 diabetes inadequately controlled on basal insulin with or without oral agents .", "", "<http://ctro/data#ClinicalTrial_49823> <http://ctro/data#hasObjectiveDescription> \"To evaluate the efficacy and long - term safety of linagliptin added to basal insulins in type 2 diabetes inadequately controlled on basal insulin with or without oral agents .\"."
3, Linagliptin, 553, 564, "linagliptin", "", 
24, Insulin, 580, 588, "insulins", "", 
27, Precondition, 592, 676, "type 2 diabetes inadequately controlled on basal insulin with or without oral agents", "", "<http://ctro/data#Population_49839> <http://ctro/data#hasPrecondition> \"type 2 diabetes inadequately controlled on basal insulin with or without oral agents\"."
9, Type2Diabetes, 592, 607, "type 2 diabetes", "", 
25, Insulin, 641, 648, "insulin", "", 
26, OralAntidiabeticAgent, 665, 676, "oral agents", "", 
55, NumberPatientsCT, 720, 727, "1 , 261", "", "<http://ctro/data#ClinicalTrial_49823> <http://ctro/data#hasNumberPatientsCT> \"1 , 261\"."
57, HbA1c, 739, 744, "HbA1c", "", 
58, Percentage, 753, 754, "%", "", 
79777, Millimoles_per_mole, 760, 770, "mmol / mol", "", 
59, Percentage, 785, 786, "%", "", 
79778, Millimoles_per_mole, 792, 802, "mmol / mol", "", 
68827, Precondition, 807, 878, "on basal insulin alone or combined with metformin and / or pioglitazone", "", "<http://ctro/data#Population_49839> <http://ctro/data#hasPrecondition> \"on basal insulin alone or combined with metformin and / or pioglitazone\"."
62, Insulin, 816, 823, "insulin", "", 
63, Metformin, 847, 856, "metformin", "", 
64, Pioglitazone, 866, 878, "pioglitazone", "", 
65, Randomized, 884, 894, "randomized", "", 
162, AllocationRatio, 897, 902, "1 : 1", "", "<http://ctro/data#AllocationRatio_49827> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#AllocationRatio>. <http://ctro/data#ClinicalTrial_49823> <http://ctro/data#hasAllocationRatio> <http://ctro/data#AllocationRatio_49827>."
66, DoubleBlind, 908, 922, "double - blind", "", 
4, Linagliptin, 938, 949, "linagliptin", "", "<http://ctro/data#Medication_49877> <http://ctro/data#hasDrug> <http://ctro/data#Linagliptin>."
164, DoseValue, 950, 951, "5", "", "<http://ctro/data#Medication_49877> <http://ctro/data#hasDoseValue> \"5\"."
70, mg, 952, 954, "mg", "", "<http://ctro/data#Medication_49877> <http://ctro/data#hasDoseUnit> <http://ctro/data#mg>."
69, Frequency, 955, 965, "once daily", "", "<http://ctro/data#Intervention_49865> <http://ctro/data#hasFrequency> \"once daily\"."
71, Placebo, 969, 976, "placebo", "", "<http://ctro/data#Medication_49884> <http://ctro/data#hasDrug> <http://ctro/data#Placebo>."
72, Duration, 981, 991, "≥ 52 weeks", "", 
73, Insulin, 998, 1011, "basal insulin", "", 
68831, DoseDescription, 998, 1158, "basal insulin dose was kept unchanged for 24 weeks but could thereafter be titrated according to fasting plasma glucose levels at the investigators ' discretion", "", 
74, Duration, 1040, 1048, "24 weeks", "", 
75, FastingPlasmaGlucose, 1095, 1117, "fasting plasma glucose", "", 
76, Mean, 1191, 1195, "mean", "", 
77, HbA1c, 1206, 1211, "HbA1c", "", 
78, TimePoint, 1217, 1225, "baseline", "", 
79, TimePoint, 1229, 1236, "week 24", "", 
80, TimePoint, 1296, 1305, "110 weeks", "", 
81, TimePoint, 1321, 1328, "week 24", "", "<http://ctro/data#Outcome_49951> <http://ctro/data#hasTimePoint> \"week 24\". <http://ctro/data#Outcome_49978> <http://ctro/data#hasTimePoint> \"week 24\"."
82, HbA1c, 1331, 1336, "HbA1c", "", "<http://ctro/data#Endpoint_49946> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
83, BaseLineValue, 1364, 1369, "8 . 3", "", "<http://ctro/data#Outcome_49951> <http://ctro/data#hasBaselineValue> \"8 . 3\"."
85, Percentage, 1370, 1371, "%", "", "<http://ctro/data#Endpoint_49946> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
84, BaseLineValue, 1374, 1376, "67", "", 
79779, Millimoles_per_mole, 1377, 1387, "mmol / mol", "", 
185, Reduction, 1395, 1400, "0 . 6", "", "<http://ctro/data#Outcome_49951> <http://ctro/data#hasChangeValue> \"0 . 6\"."
86, Percentage, 1401, 1402, "%", "", 
186, Reduction, 1407, 1412, "6 . 6", "", 
79780, Millimoles_per_mole, 1413, 1423, "mmol / mol", "", 
191, Increment, 1433, 1438, "0 . 1", "", "<http://ctro/data#Outcome_49978> <http://ctro/data#hasChangeValue> \"0 . 1\"."
87, Percentage, 1439, 1440, "%", "", 
192, Increment, 1443, 1448, "1 . 1", "", 
79781, Millimoles_per_mole, 1449, 1459, "mmol / mol", "", 
5, Linagliptin, 1467, 1478, "linagliptin", "", 
99, Placebo, 1483, 1490, "placebo", "", 
100, DiffGroupAbsValue, 1529, 1537, "- 0 . 65", "", "<http://ctro/data#DiffBetweenGroups_50005> <http://ctro/data#hasDiffGroupAbsValue> \"- 0 . 65\"."
88, Percentage, 1538, 1539, "%", "", 
101, ConfIntervalDiff, 1542, 1570, "95 % CI - 0 . 74 to - 0 . 55", "", "<http://ctro/data#DiffBetweenGroups_50005> <http://ctro/data#hasConfIntervalDiff> \"95 % CI - 0 . 74 to - 0 . 55\"."
102, DiffGroupAbsValue, 1575, 1582, "- 7 . 1", "", 
79782, Millimoles_per_mole, 1583, 1593, "mmol / mol", "", 
103, PvalueDiff, 1598, 1610, "P < 0 . 0001", "", "<http://ctro/data#DiffBetweenGroups_50005> <http://ctro/data#hasPvalueDiff> \"P < 0 . 0001\"."
68819, Insulin, 1653, 1660, "insulin", "", 
104, TimePoint, 1702, 1709, "week 52", "", "<http://ctro/data#Outcome_50019> <http://ctro/data#hasTimePoint> \"week 52\". <http://ctro/data#Outcome_50046> <http://ctro/data#hasTimePoint> \"week 52\"."
105, Linagliptin, 1712, 1723, "linagliptin", "", 
108, ResultMeasuredValue, 1724, 1729, "2 . 6", "", "<http://ctro/data#Outcome_50019> <http://ctro/data#hasResultMeasuredValue> \"2 . 6\"."
110, BioAndMedicalUnit, 1730, 1738, "IU / day", "", "<http://ctro/data#BioAndMedicalUnit_50017> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#BioAndMedicalUnit>. <http://ctro/data#Endpoint_50014> <http://ctro/data#hasBaselineUnit> <http://ctro/data#BioAndMedicalUnit_50017>."
106, Placebo, 1741, 1748, "placebo", "", 
109, ResultMeasuredValue, 1749, 1754, "4 . 2", "", "<http://ctro/data#Outcome_50046> <http://ctro/data#hasResultMeasuredValue> \"4 . 2\"."
111, BioAndMedicalUnit, 1755, 1763, "IU / day", "", 
112, PvalueDiff, 1766, 1777, "P < 0 . 003", "", "<http://ctro/data#DiffBetweenGroups_50073> <http://ctro/data#hasPvalueDiff> \"P < 0 . 003\"."
211, ObservedResult, 1782, 1824, "resulting in no further HbA1c improvements", "", "<http://ctro/data#Outcome_50019> <http://ctro/data#hasObservedResult> \"resulting in no further HbA1c improvements\". <http://ctro/data#Outcome_50046> <http://ctro/data#hasObservedResult> \"resulting in no further HbA1c improvements\"."
107, HbA1c, 1806, 1811, "HbA1c", "", 
114, Hypoglycemia, 1842, 1854, "hypoglycemia", "", "<http://ctro/data#Endpoint_50082> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#Hypoglycemia>."
115, TimePoint, 1857, 1864, "week 24", "", "<http://ctro/data#Outcome_50092> <http://ctro/data#hasTimePoint> \"week 24\". <http://ctro/data#Outcome_50119> <http://ctro/data#hasTimePoint> \"week 24\"."
116, Linagliptin, 1867, 1878, "linagliptin", "", 
124, PercentageAffected, 1879, 1885, "22 . 0", "", "<http://ctro/data#Outcome_50092> <http://ctro/data#hasPercentageAffected> \"22 . 0\"."
117, Placebo, 1890, 1897, "placebo", "", 
125, PercentageAffected, 1898, 1904, "23 . 2", "", "<http://ctro/data#Outcome_50119> <http://ctro/data#hasPercentageAffected> \"23 . 2\"."
118, TimePoint, 1909, 1922, "treatment end", "", "<http://ctro/data#Outcome_50200> <http://ctro/data#hasTimePoint> \"treatment end\". <http://ctro/data#Outcome_50227> <http://ctro/data#hasTimePoint> \"treatment end\"."
119, Linagliptin, 1925, 1936, "linagliptin", "", 
126, PercentageAffected, 1937, 1943, "31 . 4", "", "<http://ctro/data#Outcome_50200> <http://ctro/data#hasPercentageAffected> \"31 . 4\"."
121, Placebo, 1948, 1955, "placebo", "", 
127, PercentageAffected, 1956, 1962, "32 . 9", "", "<http://ctro/data#Outcome_50227> <http://ctro/data#hasPercentageAffected> \"32 . 9\"."
123, EndPointDescription, 1971, 1985, "adverse events", "", "<http://ctro/data#EndPointDescription_50088> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_50087> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_50088>."
120, Linagliptin, 1988, 1999, "linagliptin", "", 
128, PercentageAffected, 2000, 2006, "78 . 4", "", "<http://ctro/data#Outcome_50146> <http://ctro/data#hasPercentageAffected> \"78 . 4\"."
122, Placebo, 2011, 2018, "placebo", "", 
129, PercentageAffected, 2019, 2025, "81 . 4", "", "<http://ctro/data#Outcome_50173> <http://ctro/data#hasPercentageAffected> \"81 . 4\"."
136, Mean, 2060, 2064, "Mean", "", "<http://ctro/data#Mean_50256> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_50254> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_50256>."
137, BodyWeight, 2065, 2076, "body weight", "", "<http://ctro/data#Endpoint_50254> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#BodyWeight>."
138, TimePoint, 2098, 2105, "week 52", "", "<http://ctro/data#Outcome_50259> <http://ctro/data#hasTimePoint> \"week 52\". <http://ctro/data#Outcome_50286> <http://ctro/data#hasTimePoint> \"week 52\"."
139, Linagliptin, 2108, 2119, "linagliptin", "", 
228, Reduction, 2122, 2128, "0 . 30", "", "<http://ctro/data#Outcome_50259> <http://ctro/data#hasChangeValue> \"0 . 30\"."
143, Kg, 2129, 2131, "kg", "", "<http://ctro/data#Endpoint_50254> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Kg>."
140, Placebo, 2134, 2141, "placebo", "", 
229, Reduction, 2144, 2150, "0 . 04", "", "<http://ctro/data#Outcome_50286> <http://ctro/data#hasChangeValue> \"0 . 04\"."
144, Kg, 2151, 2153, "kg", "", 
150, ConclusionComment, 2172, 2323, "Linagliptin added to basal insulin therapy significantly improved glycemic control relative to placebo without increasing hypoglycemia or body weight .", "", "<http://ctro/data#ClinicalTrial_49823> <http://ctro/data#hasConclusionComment> \"Linagliptin added to basal insulin therapy significantly improved glycemic control relative to placebo without increasing hypoglycemia or body weight .\"."
6, Linagliptin, 2172, 2183, "Linagliptin", "", 
146, Insulin, 2199, 2206, "insulin", "", 
147, Placebo, 2267, 2274, "placebo", "", 
148, Hypoglycemia, 2294, 2306, "hypoglycemia", "", 
149, BodyWeight, 2310, 2321, "body weight", "", 
151, PMID, 2380, 2388, "24062327", "", "<http://ctro/data#Publication_49816> <http://ctro/data#hasPMID> \"24062327\"."
